IN2014DN02278A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN02278A IN2014DN02278A IN2278DEN2014A IN2014DN02278A IN 2014DN02278 A IN2014DN02278 A IN 2014DN02278A IN 2278DEN2014 A IN2278DEN2014 A IN 2278DEN2014A IN 2014DN02278 A IN2014DN02278 A IN 2014DN02278A
- Authority
- IN
- India
- Prior art keywords
- integer
- formula
- group
- acyl
- diaminobutyryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/50—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04010700 | 2004-05-05 | ||
EP04030847 | 2004-12-27 | ||
PCT/EP2005/004920 WO2005105152A2 (en) | 2004-05-05 | 2005-05-06 | Lipids, lipid complexes and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN02278A true IN2014DN02278A (xx) | 2015-07-10 |
Family
ID=34967659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2278DEN2014 IN2014DN02278A (xx) | 2004-05-05 | 2005-05-06 |
Country Status (20)
Country | Link |
---|---|
US (7) | US8017804B2 (xx) |
EP (1) | EP1771206B1 (xx) |
JP (1) | JP5166022B2 (xx) |
KR (1) | KR101356935B1 (xx) |
CN (2) | CN102940891B (xx) |
AU (1) | AU2005237764B2 (xx) |
BR (1) | BRPI0509471A8 (xx) |
CA (1) | CA2565633C (xx) |
CY (1) | CY1120189T1 (xx) |
DK (1) | DK1771206T3 (xx) |
ES (1) | ES2668826T3 (xx) |
HU (1) | HUE036916T2 (xx) |
IL (1) | IL178879A (xx) |
IN (1) | IN2014DN02278A (xx) |
LT (1) | LT1771206T (xx) |
MX (1) | MXPA06012722A (xx) |
PL (1) | PL1771206T3 (xx) |
PT (1) | PT1771206T (xx) |
SI (1) | SI1771206T1 (xx) |
WO (1) | WO2005105152A2 (xx) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3222724T3 (en) | 2002-08-05 | 2018-12-03 | Silence Therapeutics Gmbh | ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES |
ES2668826T3 (es) | 2004-05-05 | 2018-05-22 | Silence Therapeutics Gmbh | Lípidos, complejos lipídicos y uso de los mismos |
US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
EP1830888B1 (en) | 2004-12-27 | 2015-08-05 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their use |
AU2013257401B2 (en) * | 2006-04-20 | 2016-03-17 | Silence Therapeutics Gmbh | Lipoplex formulations for specific delivery to vascular endothelium |
JP2009535018A (ja) * | 2006-04-20 | 2009-10-01 | サイレンス・セラピューティクス・アーゲー | Cd31の発現を阻害する手段 |
CA2649630C (en) * | 2006-04-20 | 2016-04-05 | Silence Therapeutics Ag | Lipoplex formulations for specific delivery to vascular endothelium |
AU2007276388A1 (en) * | 2006-07-21 | 2008-01-24 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
US8193246B2 (en) | 2006-12-19 | 2012-06-05 | Marina Biotech, Inc. | Lipids and lipid assemblies comprising transfection enhancer elements |
CA2686735A1 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
US9433684B2 (en) | 2008-08-19 | 2016-09-06 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
EP2350278A2 (en) * | 2008-09-23 | 2011-08-03 | Silence Therapeutics AG | Means for inhibiting the expression of orc-1 |
US8829179B2 (en) | 2009-02-18 | 2014-09-09 | Silence Therapeutics Gmbh | Means for inhibiting the expression of ANG2 |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US8359883B2 (en) * | 2009-11-13 | 2013-01-29 | Hasmukh Dholakiya | Gemstone setting |
US20110200582A1 (en) * | 2009-12-23 | 2011-08-18 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
JP5510808B2 (ja) * | 2010-03-10 | 2014-06-04 | 独立行政法人産業技術総合研究所 | 有機ナノチューブからなる核酸導入剤 |
US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
US20150017091A1 (en) | 2011-08-18 | 2015-01-15 | Cornell University | Detection and treatment of metastatic disease |
TW201726599A (zh) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
JP6495408B2 (ja) * | 2012-07-06 | 2019-04-03 | 協和発酵キリン株式会社 | カチオン性脂質 |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
EP2853595A1 (en) | 2013-09-30 | 2015-04-01 | Soluventis GmbH | NOTCH 1 specific siRNA molecules |
EP3076950A1 (en) * | 2013-12-05 | 2016-10-12 | Silence Therapeutics GmbH | Means for lung specific delivery |
WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
JP7041616B2 (ja) * | 2015-09-14 | 2022-03-24 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | リポカチオン性デンドリマーおよびその使用 |
KR101949453B1 (ko) * | 2015-12-30 | 2019-02-18 | 주식회사 삼양바이오팜 | 양이온성 지질의 선택적 합성 방법 |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
CN110114461A (zh) | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
US11458107B2 (en) * | 2016-08-25 | 2022-10-04 | The Regents Of The University Of California | Abiotic anti-VEGF nanoparticle |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
WO2018112278A1 (en) | 2016-12-14 | 2018-06-21 | Ligandal, Inc. | Methods and compositions for nucleic acid and protein payload delivery |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS |
US20210363260A1 (en) | 2017-11-13 | 2021-11-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
AU2019318079A1 (en) | 2018-08-07 | 2021-01-28 | Massachusetts Institute Of Technology | Novel Cas12b enzymes and systems |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
GB2600800B (en) | 2018-09-04 | 2023-08-16 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
WO2020051223A1 (en) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
EP3865122A1 (en) | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
JPWO2022097634A1 (xx) * | 2020-11-04 | 2022-05-12 | ||
CN113116819B (zh) * | 2021-04-24 | 2022-09-20 | 郑州大学 | 一种载siRNA纳米脂质杂化胶束及其制备方法和应用 |
CN114469863B (zh) * | 2021-11-26 | 2023-09-26 | 南方医科大学南方医院 | 甾醇脂质体作为牙髓和牙本质药物传递系统的应用 |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698628B1 (fr) * | 1992-12-02 | 1995-02-17 | Fournier Ind & Sante | Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique. |
US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
EP1489184A1 (en) | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
AU707947B2 (en) | 1995-07-21 | 1999-07-22 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
CA2217550A1 (en) * | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
US6358523B1 (en) | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
EP0975332A1 (en) | 1997-04-04 | 2000-02-02 | Valentis Inc. | Improved methods of delivery using cationic lipids and helper lipids |
AU7490098A (en) | 1997-05-15 | 1998-12-08 | Genzyme Corporation | Cationic amphiphile formulations |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
US6395713B1 (en) * | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
FR2788275B1 (fr) * | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
US7015040B2 (en) | 1999-02-26 | 2006-03-21 | Mirus Bio Corporation | Intravascular delivery of nucleic acid |
IL147089A0 (en) | 1999-07-15 | 2002-08-14 | Inex Pharmaceuticals Corp | Methods of preparing lipid-encapsulated therapeutic agents |
AU7868400A (en) * | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
MXPA02009485A (es) | 2000-03-31 | 2003-03-10 | Kirin Brewery | Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento. |
EP1355670A2 (en) | 2000-04-20 | 2003-10-29 | University of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers |
EP1328254B1 (en) | 2000-10-25 | 2007-02-21 | The University Of British Columbia | Lipid formulations for target delivery |
US6394713B1 (en) * | 2001-03-05 | 2002-05-28 | Phillip E. Yates, Sr. | Drill guide apparatus |
US20040156816A1 (en) | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
EP1663171B9 (en) | 2003-08-26 | 2009-08-19 | SmithKline Beecham Corporation | Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
ES2668826T3 (es) * | 2004-05-05 | 2018-05-22 | Silence Therapeutics Gmbh | Lípidos, complejos lipídicos y uso de los mismos |
CA2587337A1 (en) | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
EP1830888B1 (en) | 2004-12-27 | 2015-08-05 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their use |
WO2006074546A1 (en) | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
CA2649630C (en) | 2006-04-20 | 2016-04-05 | Silence Therapeutics Ag | Lipoplex formulations for specific delivery to vascular endothelium |
-
2005
- 2005-05-06 ES ES05742844T patent/ES2668826T3/es active Active
- 2005-05-06 KR KR1020067023161A patent/KR101356935B1/ko not_active IP Right Cessation
- 2005-05-06 CN CN201210472822.0A patent/CN102940891B/zh not_active Expired - Fee Related
- 2005-05-06 CN CN2005800141579A patent/CN1968714B/zh not_active Expired - Fee Related
- 2005-05-06 EP EP05742844.3A patent/EP1771206B1/en not_active Not-in-force
- 2005-05-06 LT LTEP05742844.3T patent/LT1771206T/lt unknown
- 2005-05-06 PL PL05742844T patent/PL1771206T3/pl unknown
- 2005-05-06 CA CA2565633A patent/CA2565633C/en not_active Expired - Fee Related
- 2005-05-06 BR BRPI0509471A patent/BRPI0509471A8/pt not_active Application Discontinuation
- 2005-05-06 SI SI200532204T patent/SI1771206T1/en unknown
- 2005-05-06 US US11/579,700 patent/US8017804B2/en not_active Expired - Fee Related
- 2005-05-06 MX MXPA06012722A patent/MXPA06012722A/es active IP Right Grant
- 2005-05-06 WO PCT/EP2005/004920 patent/WO2005105152A2/en active Application Filing
- 2005-05-06 DK DK05742844.3T patent/DK1771206T3/en active
- 2005-05-06 PT PT57428443T patent/PT1771206T/pt unknown
- 2005-05-06 JP JP2007512035A patent/JP5166022B2/ja not_active Expired - Fee Related
- 2005-05-06 IN IN2278DEN2014 patent/IN2014DN02278A/en unknown
- 2005-05-06 HU HUE05742844A patent/HUE036916T2/hu unknown
- 2005-05-06 AU AU2005237764A patent/AU2005237764B2/en not_active Ceased
-
2006
- 2006-10-26 IL IL178879A patent/IL178879A/en not_active IP Right Cessation
-
2011
- 2011-06-30 US US13/173,296 patent/US20110294871A1/en not_active Abandoned
- 2011-09-12 US US13/230,085 patent/US8357722B2/en not_active Expired - Fee Related
-
2013
- 2013-01-16 US US13/742,700 patent/US8735453B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 US US14/286,033 patent/US9125820B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,791 patent/US9486538B2/en not_active Expired - Fee Related
-
2016
- 2016-10-20 US US15/298,261 patent/US20170036990A1/en not_active Abandoned
-
2018
- 2018-05-03 CY CY20181100470T patent/CY1120189T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN02278A (xx) | ||
NZ541974A (en) | Nucleotide phosphoramidates as anticancer agents | |
WO2001017973A3 (de) | Neue herbizide | |
SE9904652D0 (sv) | Novel Compounds | |
JO2654B1 (en) | Multiple aryl caroxa amides are useful as lipid - lowering agents | |
MXPA05009985A (es) | Ligandos de receptores de canabinoides. | |
NZ514409A (en) | C7 ester substituted taxanes as antitumor agents | |
TR200100238T2 (tr) | Yeni sübstitüe edilmiş pirazol türevleri | |
AU7278500A (en) | Fungicides | |
MXPA04004674A (es) | Ligados de los receptors de los canabinodies. | |
IL156873A0 (en) | Pharmaceutically active piperidine derivatives | |
EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
MXPA03009604A (es) | Compuestos de espiropirazol. | |
MXPA05010652A (es) | Pirazoles sustituidos. | |
AU2002351124A1 (en) | Pyrazoles-pyrimidine fungicides | |
MXPA02011370A (es) | Iminoazinas substituidas. | |
EP1490371A4 (en) | TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | |
SE0004245D0 (sv) | Novel compounds and their use | |
YU30603A (sh) | Derivati premošćenog piperazina | |
GB0317920D0 (en) | Solid-phase synthesis | |
EP1454903A4 (en) | THIADIAZOLINDERIVAT | |
MXPA05005198A (es) | Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina. | |
MXPA05010651A (es) | Compuestos de pirazol. | |
EP1555261A4 (en) | VALEROLACTONE COMPOUNDS AND FRAGRANCE COMPOSITION | |
MY125378A (en) | Pentacyclic taxan compound |